Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by HighVista Strategies LLC

HighVista Strategies LLC trimmed its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 21.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,788 shares of the company's stock after selling 17,154 shares during the quarter. Apogee Therapeutics accounts for approximately 1.3% of HighVista Strategies LLC's holdings, making the stock its 19th largest position. HighVista Strategies LLC owned approximately 0.14% of Apogee Therapeutics worth $3,629,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics during the third quarter worth about $71,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after buying an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Apogee Therapeutics in the 2nd quarter valued at about $143,000. Arizona State Retirement System lifted its holdings in shares of Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock valued at $236,000 after acquiring an additional 258 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock worth $253,000 after acquiring an additional 1,340 shares in the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the firm's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $59.22, for a total value of $888,300.00. Following the completion of the sale, the chief executive officer now directly owns 1,339,487 shares of the company's stock, valued at $79,324,420.14. This trade represents a 1.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carl Dambkowski sold 6,665 shares of the business's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $47.56, for a total transaction of $316,987.40. Following the completion of the transaction, the insider now owns 280,793 shares in the company, valued at $13,354,515.08. The trade was a 2.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 114,995 shares of company stock valued at $6,128,295. Corporate insiders own 36.10% of the company's stock.

Analyst Upgrades and Downgrades

APGE has been the subject of a number of recent research reports. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Wedbush boosted their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a research report on Monday. Guggenheim restated a "buy" rating and issued a $110.00 target price (up previously from $95.00) on shares of Apogee Therapeutics in a report on Tuesday. Finally, Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics currently has an average rating of "Buy" and a consensus target price of $83.88.

Apogee Therapeutics Trading Up 0.3 %

Apogee Therapeutics stock traded up $0.12 during mid-day trading on Tuesday, hitting $46.26. The company had a trading volume of 511,507 shares, compared to its average volume of 496,282. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -19.38 and a beta of 2.33. The company's fifty day moving average is $53.17 and its 200-day moving average is $48.33. Apogee Therapeutics, Inc. has a 12-month low of $18.84 and a 12-month high of $72.29.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.